ICON

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ICON (ICLR) reports robust earnings, eyes strategic partnerships for growth

ICON's Q4 2022 earnings reflect strong financial performance and strategic advancements. While facing challenges in pricing and COVID-related headwinds, the company is well-positioned to capitalize on growth opportunities through margin maintenance, strategic partnerships, and M&A focus.

ICON (ICLR) reports stable Q1 earnings, eyes growth amid challenges

ICON's Q1 2023 earnings call highlighted solid financial performance, strategic partnerships, and investments in innovation. While facing challenges in pricing negotiations and biotech funding, the company remains resilient and focused on growth opportunities. Stabilizing backlog burn rates, leveraging innovative tools, and addressing labor market dynamics present avenues for future success.

ICON reports solid Q2 performance and eyes growth opportunities

ICON's Q2 performance reflects growth momentum and strong financial outlook for 2023. Challenges include growth uncertainty and revenue predictability amid customer fluctuations. Opportunities lie in strategic partnerships, margin improvement, and market expansion.

ICON (ICLR) posts robust Q3 results, eyes growth amid challenges

ICON (ICLR) reports strong Q3 earnings, emphasizing revenue growth, strategic partnerships, and operational improvements. The company faces challenges from macroeconomic factors and customer concentration but sees opportunities in RFP growth and R&D budget expansion. With a focus on innovation and adaptability, ICON aims to maintain its strong performance and capitalize on future opportunities.

ICON (ICLR) reports strong Q4 earnings, eyes strategic growth

ICON's strong performance in Q4 and 2023 driven by revenue growth and margin improvement
Challenges include customer concerns over R&D spend and wide revenue guidance range for 2024
Opportunities lie in new partnerships, automation for margin expansion, and capital deployment priorities
Overall, ICON remains competitive, with positive outlook for future growth and development

ICON (ICLR) reports strong Q1 earnings and strategic growth outlook

ICON (ICLR) delivered a strong performance in Q1 2024, with robust financial results, strategic initiatives, and updated guidance reflecting confidence in future prospects.
While facing challenges such as revenue fluctuations and analyst inquiries, the company's strengths in client engagement, operational efficiency, and market positioning provide a solid foundation for growth.
Opportunities in M&A, customer base diversification, and data strategy underscore potential avenues for expansion and innovation, positioning ICON well for continued success in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October 23, 2024, ICON disclosed its financial results for the third quarter ending September 30, 2024.

Levi & Korsinsky Reminds ICON Public Limited Company Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ICLR

NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October 23, 2024, ICON disclosed its financial results for the third quarter ending September 30, 2024.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by ICON Public Limited Company (ICLR)

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October 23, 2024, ICON disclosed its financial results for the third quarter ending September 30, 2024.

Levi & Korsinsky Announces an Investigation on Behalf of ICON Public Limited Company (ICLR) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October 23, 2024, ICON disclosed its financial results for the third quarter ending September 30, 2024.

Shareholder Rights Advocates at Levi & Korsinsky Investigate ICON Public Limited Company (ICLR) Regarding Possible Securities Fraud Violations

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQ: ICLR) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Icon investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQ: ICLR) investors concerning the Company's possible violations of federal securities laws. On October 23, 2024, Icon released its third quarter 2024 financial results, missing consensus estimates “due to specific customer and division-level impacts” including “material headwinds from two large customers undergoing budget cuts and cha.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October 23, 2024, ICON disclosed its financial results for the third quarter ending September 30, 2024.

Lost Money on ICON Public Limited Company (ICLR)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

SAN DIEGO , Nov. 15, 2024 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether ICON Public Limited Company (NASDAQ: ICLR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material information adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

ICON Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

ICON Public Limited Company Being Investigated on Behalf of ICON Public Limited Company Investors. Contact Levi & Korsinsky For Details

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQ: ICLR) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On October 23, 2024, Icon released its third quarter 2024 financial results, missing consensus estimates “due to specific customer and division-level impacts” including.

The Law Offices of Frank R. Cruz Announces Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October 23, 2024, ICON disclosed its financial results for the third quarter ending September 30, 2024.

ICON Public Limited Company Being Investigated on Behalf of ICON Public Limited Company Investors. Contact Levi & Korsinsky For Details.

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the Jefferies London Healthcare Conference.

ICON plc to Present at the Jefferies London Healthcare Conference

NEW YORK, NY / ACCESSWIRE / November 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October 23, 2024, ICON disclosed its financial results for the third quarter ending September 30, 2024.

Shareholders that Lost Money on ICON Public Limited Company (ICLR) Should Contact Levi & Korsinsky About Securities Fraud Investigation - ICLR

ICON's third-quarter 2024 earnings lag estimates due to its large customers undergoing significant development model shifts with resulting cost pressures and the biotech market's slower recovery.

ICLR Misses on Q3 Earnings, Lowers 2024 Guidance, Stock Falls

ICON Public Limited Company (NASDAQ:ICLR ) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Kate Haven - Vice President of Investor Relations Steve Cutler - Chief Executive Officer Brendan Brennan - Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Michael Cherny - Leerink Partners Luke Sergott - Barclays Justin Bowers - Deutsche Bank Ann Hynes - Mizuho Patrick Donnelly - Citi David Windley - Jefferies Max Smock - William Blair Michael Ryskin - Bank of America Dan Leonard - UBS Jailendra Singh - Truist Securities Eric Coldwell - Baird Matt Sykes - Goldman Sachs Jack Meehan - Nephron Research Casey Woodring - JPMorgan Charles Rhyee - TD Cowen Operator Good day, and thank you for standing by. Welcome to the ICON PLC Q3 Earnings Conference Call and Webcast.

ICON Public Limited Company (ICLR) Q3 2024 Earnings Call Transcript

Icon PLC (ICLR) came out with quarterly earnings of $3.35 per share, missing the Zacks Consensus Estimate of $3.85 per share. This compares to earnings of $3.30 per share a year ago.

Icon PLC (ICLR) Lags Q3 Earnings and Revenue Estimates

DUBLIN--(BUSINESS WIRE)--ICON Reports Third Quarter 2024 Results.

ICON Reports Third Quarter 2024 Results

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Icon PLC (ICLR) Earnings Expected to Grow: Should You Buy?

Shares of Icon PLC (ICLR, Financial) surged 3.72% in mid-day trading on Oct 2. The stock reached an intraday high of $295.09, up from its previous close of $284.51.

Icon PLC (ICLR) Trading 3.72% Higher on Oct 2

DUBLIN--(BUSINESS WIRE)--ICON plc Schedules Third Quarter 2024 Earnings Conference Call.

ICON plc Schedules Third Quarter 2024 Earnings Conference Call

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Icon PLC (ICLR) is a Strong Value Stock

Icon PLC (ICLR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Icon PLC (ICLR) Surges 3.3%: Is This an Indication of Further Gains?

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the Baird 2024 Global Healthcare Conference.

ICON plc to Present at the Baird 2024 Global Healthcare Conference

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Icon PLC (ICLR) is a Top Value Stock for the Long-Term

Investors remain optimistic about ICON (ICLR) due to its commitment to patient access and impressive strategic pacts.

News for ICON Stock (ICLR)